SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA: SAFETY PROFILE AND ANTI‐TUMOR ACTIVITY. (17th June 2021) - Hutchings, M; Mous, R; Clausen, M. R; Johnson, P; Linton, K; Lewis, D. J; Chamuleau, M. E.D; Balari, A. S; Cunningham, D; DeMarco, D; Chen, K.‐M; Elliott, B; et al.